In this episode, Dr. Kharrazian dives into the complex world of mood disorders, shining a light on why conditions like depression and anxiety have become such significant global health challenges. He questions the mainstream approach to treating mood disorders, revealing the limitations and biases present in antidepressant research and the pharmaceutical industry's influence on published data.
Dr. Kharrazian explores what’s truly happening in the brains of those suffering from chronic mood issues, moving beyond the conventional neurotransmitter model to focus on the importance of neuronal health and plasticity. He breaks down the latest findings on treatments like ketamine, the real risks and shortcomings of long-term antidepressant use, and the many underlying biological factors—from neuroinflammation to neurodegeneration—that practitioners need to consider.
Enroll in the complete master class: Mood and Anxiety Disorders Clinical Strategies and Treatment Applications with Dr. Datis Kharrazian at:
https://pages.kharrazianinstitute.com/mood-and-anxiety-disorders
00:00 \"Anxiety Meds: Benefits and Concerns\"
03:27 Placebo Effect Outperforms Antidepressants
08:33 \"Antidepressant Trial Reporting Bias\"
10:09 \"Long-Term Antidepressant Effectiveness Questioned\"
14:43 Depression: Beyond Neurotransmitter Issues
18:06 Mood Disorders: Causes and Approaches
21:45 \"Functional Medicine & Health Education\"